CompletedPHASE1, PHASE2NCT03508687
Study of Gemcabene in Adults With FPLD
Studying OBSOLETE: Laminopathy type Decaudain-Vigouroux
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Elif Oral
- Principal Investigator
- Elif A Oral, M.D.University of Michigan
- Intervention
- 300mg Gemcabene(drug)
- Enrollment
- 5 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2019
Study locations (1)
- University of Michigan, Ann Arbor, Michigan, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03508687 on ClinicalTrials.govOther trials for OBSOLETE: Laminopathy type Decaudain-Vigouroux
Additional recruiting or active studies for the same condition.
See all trials for OBSOLETE: Laminopathy type Decaudain-Vigouroux →